Nintedanib plus Docetaxel after Immune Checkpoint Inhibitor Failure in Patients with Advanced Non-Small-Cell Lung Cancer: A Case Series

Advances in the treatment of non-small-cell lung cancers (NSCLCs) lacking an actionable driver mutation have included the approval of immunotherapies, such as monotherapy or in combination with chemotherapy. However, limited evidence exists to guide clinical decision-making after progression with im...

Descripción completa

Detalles Bibliográficos
Autores principales: Hochmair, Maximilian Johannes, Kolb, Rainer, Wurm, Robert, Zach, Herwig, Bittner, Nora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921945/
https://www.ncbi.nlm.nih.gov/pubmed/35350799
http://dx.doi.org/10.1159/000520939

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921945/
https://www.ncbi.nlm.nih.gov/pubmed/35350799
http://dx.doi.org/10.1159/000520939

Ejemplares similares